Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials

Arcus Biosciences Inc. (NYSE:RCUS) is one of billionaire Steve Cohen’s 10 small-cap stock picks with huge upside potential. On October 6, Arcus Biosciences Inc. (NYSE:RCUS) announced encouraging data for its kidney cancer drug casdatifan.

The HIF-2a inhibitor demonstrated positive results across all efficacy measures in the Phase 1/1b study. In trials involving 121 patients across four immunotherapy cohorts, the candidate drug achieved a median progression-free survival of 12.2 months.

Casdatifan showed an acceptable safety profile with anemia and hypoxia. During the trials, only 9% of the patients discontinued the treatment due to adverse events.

“Even when we analyzed pooled data for the 121 patients treated with casdatifan monotherapy, casdatifan showed a confirmed ORR of 31% and a median PFS of 12.2 months, which is meaningfully longer than published data from studies with the only marketed HIF-2a inhibitor and for TKIs alone in a similar patient population and setting,” said Richard Markus, M.D., Ph.D., chief medical officer at Arcus Biosciences.

Arcus Biosciences Inc. (NYSE:RCUS) is a clinical-stage Biopharmaceutical Company that discovers and develops novel combination therapies for cancer, focusing on both small molecules and antibodies to address unmet medical needs.

While we acknowledge the potential of RCUS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Stocks to Buy As Gold Rallies and 13 Stocks to Buy According to Billionaire Ray Dalio’s Bridgewater Associates.

Disclosure: None. This article is originally published at Insider Monkey.